Back to top
more

Bausch Health (BHC)

(Real Time Quote from BATS)

$5.73 USD

5.73
531,940

-0.21 (-3.54%)

Updated Aug 6, 2025 12:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar

by Zacks Equity Research

Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.

Zacks Equity Research

Is Bausch Health Cos (BHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (BHC) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Generic Industry on Path to Recovery: 3 Hot Picks for 2019

by Zacks Equity Research

The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

Zacks Equity Research

Should Value Investors Buy Bausch Health (BHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

BHC vs. AMPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

BHC vs. AMPH: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Barclays, Bausch Health, Canadian Solar, DAQO and Tech Data

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Barclays, Bausch Health, Canadian Solar, DAQO and Tech Data

Nilanjan Banerjee headshot

7 Incredible Value Stocks to Pick for 2019

by Nilanjan Banerjee

Given a plummeting global stock market, it is the best time to bet on stocks that are currently undervalued.

Zacks Equity Research

Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals

by Zacks Equity Research

Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.

Zacks Equity Research

Should Value Investors Buy Bausch Health (BHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BHC) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Why Is Bausch (BHC) Down 9.8% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 4th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Zacks Equity Research

Zacks Market Edge Highlights: CF Industries, Mosaic, Etsy, Lululemon and Bausch Health

by Zacks Equity Research

Zacks Market Edge Highlights: CF Industries, Mosaic, Etsy, Lululemon and Bausch Health

Zacks Equity Research

BHC or AMPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BHC vs. AMPH: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BHC) Outperforming Other Medical Stocks This Year?

Tracey Ryniec headshot

5 Top Stocks That Aren't FAANG

by Tracey Ryniec

With the FAANG stocks entering into a bear market, now is the time to diversify your portfolio with other companies with strong fundamentals.

Tracey Ryniec headshot

5 Top Stocks That Aren???t FAANG

by Tracey Ryniec

With the FAANG stocks entering into a bear market, now is the time to diversify your portfolio with other companies with strong fundamentals.

Zacks Equity Research

Is Bausch Health (BHC) a Great Stock for Value Investors?

by Zacks Equity Research

Let's see if Bausch Health (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Why Bausch (BHC) Might be Well Poised for a Surge

by Zacks Equity Research

Bausch (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for November 12th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

Zacks Equity Research

Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

by Zacks Equity Research

Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

Zacks Equity Research

Bausch Health (BHC) Is Up 5.78% in One Week: What You Should Know

by Zacks Equity Research

Does Bausch Health (BHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Are Investors Undervaluing Bausch Health (BHC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 32.18% and 2.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Community Health's (CYH) Q3 Loss Widens, Admissions Drop

by Zacks Equity Research

Community Health (CYH) suffers from loss from drop in admissions.